{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Baseline Assessments', 'At Day 1 and prior to randomization, any changes to the eligibility parameters must be', 'assessed and any results required prior to randomization (e.g., Day 1 urine pregnancy test', 'for women of childbearing potential) must be available and reviewed.', 'Other baseline information to be collected at Day 1 includes assessment of HIV risk', 'factors and mode of transmission, general medical history and current medical', 'conditions, and menopause history. Laboratory and health outcomes assessments will', 'also be collected. Questionnaire/surveys are recommended to be administered at the', 'beginning of the visit before any other assessments are conducted. Refer to Section 1.3', 'for a summary of all procedures at the Baseline (Day 1) visit.', '8.1.', 'Efficacy Assessments', 'Plasma HIV-1 RNA', 'Plasma for quantitative HIV-1 RNA will be collected according to the Schedule of', 'Activities (Section 1.3). Methods to be used may include but are not limited to the', 'Abbott Realtime HIV-1 Assay lower limit of quantitation 40 c/mL. In some cases, (e.g.,', 'where the plasma HIV-1 RNA is below the lower limit of detection for a given assay)', 'additional exploratory methods may be used to further characterize plasma HIV-1 RNA', 'levels.', 'Lymphocyte Subsets', 'Lymphocyte subsets will be collected for assessment by flow cytometry (total', 'lymphocyte counts, percentage, and absolute CD4+ and CD8+ lymphocyte counts,', 'CD4+/CD8+ ratio) according to the Schedule of Activities (Section 1.3).', 'CDC HIV-1 Classification and HIV Associated Conditions', 'HIV-associated conditions will be recorded as per the Schedule of Activities (Section', '1.3). HIV associated conditions will be assessed according to the 2014 CDC Revised', 'Classification System for HIV Infection in Adults (see Section 11.12). When assessing', 'CDC stage at Screening/Baseline, consider only the latest available CD4 T-cell count,', 'except when the participant had an active Stage 3 event in the 6 months prior to', 'Screening. Indicators of clinical disease progression are defined as:', 'CDC Stage 1 at enrolment', 'Stage 3 event;', 'CDC Stage 2 at enrolment', 'Stage 3 event;', 'CDC Stage 3 at enrolment', 'New Stage 3 Event;', 'CDC Stage 1, 2 or 3 at enrolment', 'Death.', '8.1.1.', 'Primary Efficacy Endpoint', 'The primary endpoint will be the proportion of participants with virologic failure', 'endpoint as per FDA snapshot category at week 48 for the ITT-E population. Virologic', '59']['2017N331008_06', 'CONFIDENTIAL', '208090', 'failure will include the following events; data in window not below 50 c/mL,', 'discontinued for lack of efficacy, discontinued for other reason while not below 50 c/mL,', 'and change in background therapy.', '8.1.2.', 'Secondary Efficacy Endpoints', 'Proportion of participants with plasma HIV-1 RNA <50 c/mL at Weeks 24 and 48', 'using the Snapshot algorithm for the ITT-E population', 'Percentage of participants with viral failure endpoint as per FDA snapshot category', 'at', 'Weeks 24', 'Change from Baseline in CD4+ lymphocyte count and in CD4+/CD8+ cell counts', 'ratio at Weeks 24 and 48', 'Incidence of disease progression (HIV-associated conditions, AIDS and death).', '8.2.', 'Safety Assessments', 'Planned time points for all safety assessments are provided in the Schedule of Activities', '(SoA) (Section 1.3).', '8.2.1.', 'Physical Examinations', 'Physical exams should be conducted as part of normal routine clinical care but will not be', 'collected systematically in the eCRF. Abnormalities noted during any exam must be', 'recorded in the eCRF (e.g. in the current medical conditions or AE logs).', '8.2.2.', 'Vital Signs', 'At the Screening visit, vital signs including height, weight and Body Mass Index', '(BMI) will be measured. The systolic and diastolic blood pressure will be measured', 'in semi-supine position after 5 minutes rest. Body weight and BMI will also be', 'assessed at each visit according to the Schedule of Activities (SoA) (Section 1.3).', '8.2.3.', 'Electrocardiograms', 'A baseline 12-lead ECG will be conducted at the Screening visit, for possible use as', 'a reference during the study (i.e. in evaluation of any pertinent cardiovascular event).', '8.2.4.', 'Clinical Safety Laboratory Assessments', 'Refer to Appendix 7 for the list of clinical laboratory tests to be performed and to the', 'SoA (Section 1.3) for the timing and frequency. All protocol required laboratory', 'assessments must be performed by central laboratory services, with the exception of', 'exceptional circumstances during screening noted in Section 5. Please refer to Appendix', '14 in Section 11.14 for study management information during the COVID-19 pandemic.', 'Laboratory assessments must be conducted in accordance with the Laboratory Manual,', 'and SoA (Section 1.3). Laboratory requisition forms must be completed and samples', '60']\n\n###\n\n", "completion": "END"}